HYR PB21
Alternative Names: HYR-PB21Latest Information Update: 28 Apr 2023
At a glance
- Originator Hefei Cosource Pharmaceutical
- Class Anaesthetics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Postoperative pain
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for phase-I development in Postoperative-pain(In volunteers) in Australia (SC, Injection)
- 03 Mar 2020 Phase-I clinical trials in Postoperative pain (In volunteers) in Australia (SC) (NCT04169256)